Home/Filings/4/0000950170-25-100373
4//SEC Filing

Poulton Stuart 4

Accession 0000950170-25-100373

CIK 0001503802other

Filed

Jul 29, 8:00 PM ET

Accepted

Jul 30, 4:56 PM ET

Size

4.8 KB

Accession

0000950170-25-100373

Insider Transaction Report

Form 4
Period: 2025-07-29
Poulton Stuart
EVP, Chief Development Officer
Transactions
  • Sale

    Common Stock

    2025-07-29$4.37/sh191$83527,223 total
Footnotes (1)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Documents

1 file

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001942597

Filing Metadata

Form type
4
Filed
Jul 29, 8:00 PM ET
Accepted
Jul 30, 4:56 PM ET
Size
4.8 KB